Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia Aug 15, 2023
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030 Jul 25, 2023
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors Jul 5, 2023
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe May 25, 2023
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America May 23, 2023
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer Mar 28, 2023
